Market Overview

The global Diabetes Care Devices Market was valued at USD 34.19 Billion in 2024 and is forecasted to reach USD 62.65 Billion by 2033, exhibiting a CAGR of 6.61% between 2025 and 2033. Growth is driven by the rising diabetes incidence, technological advancements such as continuous glucose monitoring and smart insulin pens, favorable government initiatives, increasing disposable incomes, and the aging population. North America dominates with over 38.6% market share in 2024.

Study Assumption Years

• Base Year: 2024
• Historical Period: 2019-2024
• Forecast Period: 2025-2033

Diabetes Care Devices Market Key Takeaways

• Current Market Size: USD 34.19 Billion in 2024
• CAGR: 6.61% (2025-2033)
• Forecast Period: 2025-2033
• North America holds the largest share at over 38.6% in 2024.
• Demand surges due to increased diabetes prevalence, technological innovation, and government policies.
• The U.S. market accounts for 89.5% of North America’s market share, with strong adoption of home-based diabetes management solutions.
• Growth is supported by well-established healthcare infrastructure and reimbursement schemes, especially for CGM devices.
• Artificial intelligence and cloud-based analytics are enhancing remote monitoring capabilities.

Sample Request Link: https://www.imarcgroup.com/diabetes-care-devices-market/requestsample

Market Growth Factors

The rising incidence of diabetes worldwide is a dominant force behind market expansion. Sedentary lifestyles and high-sugar, high-fat diets contribute to increasing cases. As per the report, 537 million adults had diabetes in 2021, predicted to reach 783 million by 2045. This growth creates urgent demand for effective monitoring and management devices that improve glucose control, reduce complications, and provide real-time data for clinical decisions.

Rapid technological advancements drive significant market growth. Continuous Glucose Monitoring (CGM) systems offer real-time glucose profiles, enhancing patient compliance and treatment personalization. The CGM market is projected to achieve USD 20 Billion in sales by 2028. Smart insulin pens with dose calculators and connected devices enable easy data sharing with healthcare professionals, facilitating better diabetes management and accelerating adoption.

Favorable government initiatives play a critical role in market development. Many governments recognize diabetes as a public health challenge and allocate funds for subsidizing device costs to improve accessibility. Information campaigns, reimbursement programs, and supportive policies facilitate device penetration, especially continuous glucose monitors. These initiatives reduce economic burden and promote early diagnosis and management.

Market Segmentation

By Type:

• Blood Glucose Monitoring (BGM) Devices:
• Self-Monitoring Devices
• Continuous Glucose Monitoring Devices
• Insulin Delivery Devices:
• Pumps
• Pens
• Syringes
• Jet Injectors

*Description:* Blood Glucose Monitoring (BGM) Devices lead with around 65.8% market share in 2024. They are highly affordable, user-friendly, require just a small blood drop for precise readings, deliver results rapidly, and are portable for on-the-go monitoring. They enjoy broad healthcare provider acceptance and require minimal upkeep.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Diabetes Clinics/Centers
• Online Pharmacies
• Others

*Description:* Hospital pharmacies dominate with about 54.7% market share in 2024. They are trusted for device authenticity and quality, provide expert pharmacist advice, ensure easy access during hospital visits, streamline insurance claims, and offer a broad device selection.

By End User:

• Hospitals
• Homecare
• Diagnostic Centers
• Ambulatory Surgery Centers

*Description:* Hospitals lead the end-user segment with around 40.5% share in 2024. They offer comprehensive diabetes care services including expert consultations and emergency handling, benefit from insurance coverage, and buy devices in bulk, ensuring quality and safety standards.

Regional Insights

North America leads the market with a share of over 38.6% in 2024, attributed to the region's high diabetes prevalence and advanced healthcare infrastructure. Comprehensive insurance coverage and ongoing technological innovation by leading medical device manufacturers support rapid adoption of diabetes care devices. Government policies and increasing public awareness further bolster market growth.

Recent Developments & News

• September 2024: FDA cleared the Eversense 365 system, a long-term continuous glucose monitoring device with a one-year sensor lifespan, enhancing accuracy and user comfort; launch planned for early Q4 2024.
• August 2024: Abbott partnered globally with Medtronic to integrate Abbott's FreeStyle Libre CGM with Medtronic’s automated insulin delivery and smart insulin pen systems, aiming to improve health outcomes.
• March 2024: Roche showcased its Accu-Chek SmartGuide CGM at a major diabetes conference, featuring real-time monitoring with high accuracy (MARD 9.2%) and predictive hypoglycemia alerts.
• March 2024: FDA approved Dexcom's Stelo, the first glucose biosensor without prescription, for adults with Type 2 diabetes not on insulin; launch scheduled for summer 2024.
• March 2023: Becton Dickinson introduced the BD™ Diabetes Care App, providing self-management tools, educational resources, and personal goal tracking for diabetes care.

Key Players

• Abbott Laboratories
• ACON Laboratories Inc.
• Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation)
• Becton Dickinson and Company
• Bionime Corporation
• Dexcom Inc.
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Medtronic plc
• Novo Nordisk A/S
• Sinocare Inc.
• Terumo Corporation

Customization Note

If you require any specific information that is not currently covered within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=5746&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302